{"id":"W2118132357","doi":"10.1186/2193-1801-3-419","title":"The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies","year":2014,"lang":"en","type":"article","venue":"SpringerPlus","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"European Respiratory Society","keywords":"Formoterol; Medicine; Placebo; Bronchodilator; COPD; Crossover study; Morning; Anesthesia; Formoterol Fumarate; Internal medicine; Asthma; Inhalation; Budesonide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003580578,0.001142173,0.003263008,0.000410972,0.0003783139,0.001112757,0.0005860534,0.001543894,0.002215735],"category_scores_gemma":[0.003667484,0.00061266,0.002710568,0.0003752806,0.0008783236,0.001423542,0.0004021625,0.002308763,0.0008188593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004749211,"about_ca_system_score_gemma":0.0004653222,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004261354,"about_ca_topic_score_gemma":0.0005770978,"domain_scores_codex":[0.9982009,0.000920755,0.0002029379,0.0003397007,0.0001711164,0.0001646747],"domain_scores_gemma":[0.9963917,0.001094289,0.0009366308,0.0004747556,0.0003587555,0.0007439636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8950526,0.02829593,0.006284773,0.0009452208,0.002489905,0.0001063804,0.0003856414,0.0003415263,0.03447149,0.00004527827,0.0003415115,0.0312397],"study_design_scores_gemma":[0.2272159,0.726549,0.03891207,0.00004198451,0.001556918,0.0001122222,0.0001133273,0.0003727201,0.00414328,0.00006286174,0.0008546502,0.00006507589],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965442,0.002094369,0.0003116067,0.00007566759,0.00009314207,0.0003497576,0.0002498954,0.00002349332,0.0002577473],"genre_scores_gemma":[0.9968528,0.000806316,0.0006562665,0.0001526701,0.0001667893,0.0003291847,0.0004077944,0.00001508129,0.000613055],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003580578,"threshold_uncertainty_score":0.01893616,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01321654566217633,"score_gpt":0.271793410684639,"score_spread":0.2585768650224626,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}